Stress strain curves (from a1 to f1), stress—AE count plots (from a2 to f2) and stress—cumulative AE count plots (from a3 to f3) for the sample temperatures of 20°C, 50°C, 100°C, 1... by Nazlı Tunar Özcan (14833635)

Concentration indices that show socioeconomic inequalities in child undernutrition in Ethiopia (DHS 2005 to 2016). by Frehiwot Birhanu (17507395)

Subjects:

Concentration curve that shows socioeconomic inequalities in child undernutrition in Ethiopia (DHS 2005 to 2016). by Frehiwot Birhanu (17507395)

Subjects:

Sampling procedure for the Ethiopian Demographic and Health Surveys. by Frehiwot Birhanu (17507395)

Subjects:

Multilevel mixed-effect Poisson regression: Pooled data (DHS: 2005 to 2016). by Frehiwot Birhanu (17507395)

Subjects:

Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections by Mostafa A. Elfawal (22430138)

“…The unexpected SAR of compound <b>15</b> can be explained by computational modeling. We demonstrate the efficacy of optimized compound <b>50</b> as a new oral anthelmintic, which demonstrated better gut restriction properties and significantly reduced the fecundity of T. muris whipworm adults in infected mice. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

Luciferase reporter expression analysis in A427-derived xenograft tumors following IT injection of rH17d’-Ad5 vectors. by Christopher M. Gentile (6640331)

A decreased yield of RNP1, RNP2 and RNP5 formation in the presence of protein aGAR1 is counteracted by RNA-S by Bruno Charpentier (9519)

PCA analysis of QMP residues recovered from nest worker bodies at different seasonal time points. by Mark J. Carroll (3605582)

Whole sample storing experiment: Mean FECs of day 0, day 1 and day 2 for hookworm, <i>A</i>. <i>lumbricoides</i> and <i>T</i>. <i>trichiura</i>. by Felix Bosch (10024550)

Inhibition of ILK Decreases Bipolar and Multipolar Cytokinesis while Increasing Survival of Multinucleated Cells. by William K. A. Sikkema (574881)

Assessment of calcium events, pERK levels, NMDA receptor expression and extracellular zinc levels in <i>slc13a5</i> mutants. by Deepika Dogra (21072023)

“…White arrowheads point to Slc13a5⁺/Grin1⁺ cells in MB. …”

Total BAL cell numbers and cell differential counts. by Ana Fernandez-Bustamante (766266)

Definitions of social influence metrics (i.e., betweenness centrality or age category) network level indices (weighted (W) diameter, global efficiency and modularity, as well as un... by Maggie Wiśniewska (11965538)

Measurements of HO-1 and dephosphorylated p38-MAPK concentrations in alveolar macrophages. by Ana Fernandez-Bustamante (766266)

Lung injury features. by Ana Fernandez-Bustamante (766266)

S2 File - by Yosuke Kameno (342665)

“…This initial increase and subsequent decrease in K6 and FCV-19S were more prominent in individuals with high trait anxiety (K6: B = 1.55, 95% CI = 1.18 to 1.91; FCV-19S: B = 4.27, 95% CI = 2.50 to 6.04) and in occupations other than physicians or nurses. …”

S1 File - by Yosuke Kameno (342665)

“…This initial increase and subsequent decrease in K6 and FCV-19S were more prominent in individuals with high trait anxiety (K6: B = 1.55, 95% CI = 1.18 to 1.91; FCV-19S: B = 4.27, 95% CI = 2.50 to 6.04) and in occupations other than physicians or nurses. …”